Lots of talk about new medicaid rules, data, metrics, scores, MLR, network adequacy and more. Lots of new data sources on the way in and out MSIS and TMSIS, oh my! Here's something just for fun we thew together. Wonder how medicaid docs do versus medicaid doctors? Is supply aligned with demand (prevalence and provider coverage)? How about unnecessary spend and no value care? Crazier still, think they could succeed in risk arrangements?
Lots of talk about new medicaid rules, data, metrics, scores, MLR, network adequacy and more. Lots of new data sources on the way in and out MSIS and TMSIS, oh my! Here's something just for fun we thew together. Wonder how medicaid docs do versus medicaid doctors? Is supply aligned with demand (prevalence and provider coverage)? How about unnecessary spend and no value care? Crazier still, think they could succeed in risk arrangements?
Larry Levitt: "Out of Pocket: Surprise Costs After Health Reform," 10.29.15reportingonhealth
Larry Levitt's presentation from "Out of Pocket: Surprise Costs After Health Reform," 10.29.15
http://www.reportingonhealth.org/content/out-pocket-surprise-costs-after-health-reform
ACA: Evidence-Based Update - 2015 Policy Prescriptions® SymposiumCedric Dark
The symposium is designed for clinicians – physicians, nurses, nurse practitioners, physician assistants, and students – and healthcare executives interested in expanding their scope of knowledge about currently popular health policy topics.
This presentation is by Dr. Seth Trueger. Dr. Trueger is an emergency physician in Chicago whose interests include social media for health professions, payment and delivery reform, crowding, airway, and resuscitation. He is the Assistant Social Media Editor for Annals of Emergency Medicine. He worked as a health fellow / legislative aide in the office of Congressman John Dingell (D-MI) from 9/2013-3/2014 (while still seeing patients, of course). And since January 1, 2013, has served as the Social Media (Twitter) Editor for Emergency Physicians Monthly. You can follow him on Twitter @MDAware or online at MDAware[dot]org.
See who breaching, who's breaking, and who is complying with the Sunshine Act in 2015:
54 Companies pay >$2,500 to Individual Californian Docs
Av. Food & Bev payment now $24
Pharma eradicates Entertainment
Gulf widens between pharma. & medtech payments
This is from a brief workshop we did at Arizona SkySong for local health care executives. All about the current state of value-based care, accountable care organizations, and general trends we're seeing within the health care delivery space.
Sunshine Act Compliance Analysis by WorldDataOnline. Comprehensive, individual, and highly specific company reports will be available shortly. https://worlddata.online/Product/Subscription/LATEST---2015---Sunshine-Act-Compliance-Analyzer
Obamacare in Pictures: Visualizing the Effects of the Patient Protection and ...The Heritage Foundation
“Obamacare in Pictures: Visualizing the Effects of the Patient Protection and Affordable Care Act” shows in detail the impact of the sweeping health care law for Americans.
How to Efficiently and Effectively Help Consumers Navigate Plan SelectionEnroll America
Learn how to effectively and efficiently help consumers through the plan selection process and how to breakdown some of the difficult health insurance concepts when working with the remaining uninsured and newly enrolled.
Donor Government Disbursements for Family Planning in 2017 (Slideshow)KFF
Donor government funding for family planning increased in 2017, rising from $1.20 billion in 2016 to $1.27 billion (an increase of $74 million or 6%, as measured in current terms); funding increased even after accounting for inflation and currency fluctuations.
2019 KFF Employer Health Benefits Survey ChartpackKFF
The 2019 Employer Health Benefits Survey finds annual family premiums for employer health insurance rose 5% to average $20,576 this year. On average, workers pay $6,015 toward the cost.
How Abortion Policies Changed in Medicaid and Private Insurance, 2000-2019KFF
This slideshow shows how policies on abortion coverage in Medicaid and Private Insurance has changed since 2000 (before the passage of the ACA) until present-day.
This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage including premiums, employee contributions, cost-sharing provisions, offer rates, wellness programs, and employer practices. The 2018 survey included 2,160 interviews with non-federal public and private firms.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Share of Plans by Type of Cost Sharing for Primary Care Physician
Visits (deductible may apply first)
1% 2%
1%
32%
10%
4%
39%
73% 83% 92%
24%
13%
10%
6%6% 3% 2%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Bronze Silver Gold Platinum
Copay & Coinsurance
Coinsurance
Copayment
No Charge after Deductible
No Charage
3. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Average Copayments for Primary Care Physician Visits
$37
$28
$22
$19
$0
$5
$10
$15
$20
$25
$30
$35
$40
Bronze Silver Gold Platinum
4. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Distribution of Copayments for Primary Care Physician Visits
1%
15%
20%
25%
17%
12%
28%
26%
18%
50%
45%
47%
40%
12%
4%
1%
14%
10%
3% 1%
10%
1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Bronze Silver Gold Platinum
Over $50
>$40 - $50
>$30 - $40
>$20 - $30
>$10 - $20
$10 or less
5. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Average Coinsurance Rates for Primary Care Physician Visits
33%
26%
21% 21%
0%
5%
10%
15%
20%
25%
30%
35%
Bronze Silver Gold Platinum
6. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Distribution of Coinsurance Rates for Primary Care Physician Visits
5%
17%
24%
42%
26%
36%
56%
26%
17%
30%
13%
16%
32%
5%
2%
18%
12%
5%
16%
1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Bronze Silver Gold Platinum
Over 50%
>40% - 50%
>30% - 40%
>20% - 30%
>10% - 20%
10% or less
7. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Share of Plans by Type of Cost Sharing for Specialist Physician Visits
(deductible may apply first)
34%
11%
4% 1%
33%
70% 81%
91%
30%
18%
13%
8%
3% 2% 2%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Bronze Silver Gold Platinum
Copay & Coinsurance
Coinsurance
Copayment
No Charge after Deductible
8. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Average Copayments for Specialist Physician Visits
$65
$56
$44
$29
$0
$10
$20
$30
$40
$50
$60
$70
Bronze Silver Gold Platinum
9. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Distribution of Copayments for Specialist Physician Visits
3%1% 2%
13%
47%
40%
47%
71%
48%
34%
45%
16%
2%
20%
5%5%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Bronze Silver Gold Platinum
Over $100
>$75 - $100
>$50 - $75
>$25 - $50
>$10 - $25
$10 or less
10. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Average Coinsurance Rates for Specialist Physician Visits
34%
26%
19% 19%
0%
5%
10%
15%
20%
25%
30%
35%
40%
Bronze Silver Gold Platinum
11. SOURCE: Kaiser Family Foundation analysis of Marketplace plans in the 37 states with Federally Facilitated or Partnership exchanges in 2015
(including New Mexico, Oregon, and Nevada). Data are from Healthcare.gov Health plan information for individuals and families available here:
https://www.healthcare.gov/health-plan-information/
Distribution of Coinsurance Rates for Specialist Physician Visits
5%
16%
28%
52%
25%
34%
56%
22%
18%
31%
11%
13%
31%
6%
2%
0%
20%
14%
4%
13%
1% 0%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Bronze Silver Gold Platinum
Over 50%
>40% - 50%
>30% - 40%
>20% - 30%
>10% - 20%
10% or less